Darwin Global Management, Ltd. - Q2 2021 holdings

$620 Million is the total value of Darwin Global Management, Ltd.'s 12 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 166.7% .

 Value Shares↓ Weighting
NTLA NewINTELLIA THERAPEUTICS INC$301,141,0001,859,926
+100.0%
48.58%
XLRN BuyACCELERON PHARMA INC$220,906,000
+8.2%
1,760,346
+17.0%
35.63%
-10.8%
BEAM NewBEAM THERAPEUTICS INC$16,344,000126,985
+100.0%
2.64%
VERV NewVERVE THERAPEUTICS INC$6,207,000103,013
+100.0%
1.00%
INBX BuyINHIBRX INC$6,205,000
+521.7%
225,480
+353.6%
1.00%
+413.3%
EPIX NewESSA PHARMA INC$5,958,000208,524
+100.0%
0.96%
KROS BuyKEROS THERAPEUTICS INC$4,425,000
-17.3%
104,186
+19.9%
0.71%
-31.8%
ACRS NewACLARIS THERAPEUTICS INC$4,390,000250,000
+100.0%
0.71%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
FATE THERAPEUTICS INC5Q4 202124.2%
KEROS THERAPEUTICS INC5Q1 202312.8%
INHIBRX INC5Q4 20213.9%
ACCELERON PHARMA INC4Q3 202163.4%
AMBRX BIOPHARMA INC4Q3 202367.5%
ARGENX SE4Q3 202370.2%
BRIDGEBIO PHARMA INC4Q3 202125.2%
FULCRUM THERAPEUTICS INC4Q4 20210.9%
ASTRAZENECA PLC3Q2 2022100.0%
INTELLIA THERAPEUTICS INC3Q4 202148.6%

View Darwin Global Management, Ltd.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
42023-06-28
SC 13D/A2023-06-28
SC 13D/A2023-05-25
13F-HR2023-05-15
SC 13G2023-04-03
32023-03-08

View Darwin Global Management, Ltd.'s complete filings history.

Compare quarters

Export Darwin Global Management, Ltd.'s holdings